How big is Lifecore Biomedical, Inc.?

As of Jun 18, Lifecore Biomedical, Inc. has a market capitalization of 252.14 million, with net sales of 130.30 million and a net profit of -44.66 million over the last four quarters. The company reported shareholder's funds of 53.90 million and total assets of 273.70 million as of May 24.

Market Cap: As of Jun 18, Lifecore Biomedical, Inc. has a market capitalization of 252.14 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Lifecore Biomedical reported net sales of 130.30 million and a net profit of -44.66 million.<BR><BR>Balance Sheet Snapshot: As of May 24, the company reported shareholder's funds of 53.90 million and total assets of 273.70 million.

What does Lifecore Biomedical, Inc. do?

Lifecore Biomedical, Inc. designs and manufactures health and wellness products in the Pharmaceuticals & Biotechnology sector, with recent net sales of $35 million and a net loss of $15 million. The company has a market cap of $252.14 million and operates in the micro-cap market.

Overview:<BR>Lifecore Biomedical, Inc. designs, develops, manufactures, and sells health and wellness products primarily in the Pharmaceuticals & Biotechnology industry, operating within the micro-cap market.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 35 Million (Quarterly Results - Feb 2025) <BR>Most recent Net Profit: -15 Million (Quarterly Results - Feb 2025) <BR>Market-cap: USD 252.14 Million (Micro Cap)<BR><BR>Key Metrics:<BR>Debt Equity: 2.48 <BR>Return on Equity: -89.08% <BR>Price to Book: 5.32 <BR><BR>Contact Details:<BR>Address: 5201 Great America Pkwy Ste 232, SANTA CLARA CA: 95054-1126 <BR>Tel: 1 650 3061650 <BR>Website: https://www.landec.com/

Should I buy, sell or hold Lifecore Biomedical, Inc.?

Who are in the management team of Lifecore Biomedical, Inc.?

As of March 2022, the management team of Lifecore Biomedical, Inc. includes Independent Chairman Mr. Craig Barbarosh, President and CEO Dr. Albert Bolles, and Directors Mr. Jeffrey Edwards, Mr. Joshua Schechter, Mr. Patrick Walsh, Independent Director Ms. Deborah Carosella, and Independent Director Ms. Katrina Houde. They oversee the company's operations and strategic direction.

As of March 2022, the management team of Lifecore Biomedical, Inc. includes the following individuals:<BR><BR>- Mr. Craig Barbarosh, who serves as the Independent Chairman of the Board.<BR>- Dr. Albert Bolles, who is the President, Chief Executive Officer, and a Director.<BR>- Mr. Jeffrey Edwards, who is a Director.<BR>- Mr. Joshua Schechter, who is a Director.<BR>- Mr. Patrick Walsh, who is a Director.<BR>- Ms. Deborah Carosella, who is an Independent Director.<BR>- Ms. Katrina Houde, who is also an Independent Director. <BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

Is Lifecore Biomedical, Inc. overvalued or undervalued?

As of January 2, 2025, Lifecore Biomedical, Inc. is considered overvalued with a risky valuation grade, reflected by a high Price to Book Value of 5.35, negative EV to EBIT and EV to EBITDA ratios, and poor ROCE and ROE metrics, despite a strong 1-year stock return of 52.50%.

As of 2 January 2025, Lifecore Biomedical, Inc. has moved from a fair to a risky valuation grade. The company appears to be overvalued given its high Price to Book Value of 5.35 and negative EV to EBIT and EV to EBITDA ratios of -30.78 and -81.49, respectively. Additionally, the company's ROCE stands at -7.31% and ROE at -89.08%, indicating significant financial distress.<BR><BR>In comparison to its peers, Lifecore Biomedical's EV to EBITDA ratio of -96.8085 is notably worse than scPharmaceuticals, Inc. at -4.6432 and Vanda Pharmaceuticals, Inc. at 0.5601. This suggests that Lifecore is underperforming relative to its industry counterparts. Despite a strong 1-year stock return of 52.50% compared to the S&P 500's 17.14%, the long-term performance over 3 and 5 years shows declines of -17.99% and -20.78%, respectively, reinforcing the notion of overvaluation.

Is Lifecore Biomedical, Inc. technically bullish or bearish?

As of August 25, 2025, Lifecore Biomedical, Inc. shows a mildly bullish trend with strong daily moving averages and bullish Bollinger Bands, despite some bearish signals from weekly indicators and underperformance over longer periods.

As of 25 August 2025, the technical trend for Lifecore Biomedical, Inc. has changed from bullish to mildly bullish. The weekly MACD and KST indicators are mildly bearish, while the monthly MACD and KST are bullish. The daily moving averages are bullish, and Bollinger Bands are bullish on both weekly and monthly time frames. However, Dow Theory and OBV indicate a mildly bearish stance on the weekly and monthly charts. <BR><BR>In terms of performance, the stock has outperformed the S&P 500 over the past week and month, returning 2.06% and 7.16% respectively, but has underperformed over the year-to-date and longer periods. Overall, the current technical stance is mildly bullish, driven by strong daily moving averages and bullish Bollinger Bands, despite some bearish signals on the weekly indicators.